查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2021500

神經回饋平台市場預測至2034年－全球分析（按組件、模式、平台類型、年齡層、應用、最終用戶和地區分類）

Neurofeedback Platforms Market Forecasts to 2034 - Global Analysis By Component (Hardware, Software and Services), Modality, Platform Type, Age Group, Application, End User, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球神經反饋平台市場規模將達到 13 億美元，並在預測期內以 12.7% 的複合年成長率成長，到 2034 年將達到 34 億美元。

神經回饋平台是指一種整合了臨床和消費應用功能的系統，它透過腦電圖（EEG）、功能性磁振造影（fMRI）、腦血流圖或延遲皮質電位記錄等技術即時測量大腦的電活動，並提供即時的聽覺、視覺或觸覺回饋訊號，以訓練使用者調節自我調節與注意力、放鬆、認知功能和神經系統症狀管理模式的特定神經系統症狀管理。這些平台包括配備電極的頭戴式耳機、訊號放大硬體、即時訊號處理軟體、遊戲化訓練介面、會話管理入口網站以及進度追蹤和分析功能，並被用於治療注意力不足過動症（ADHD）、焦慮症管理、巔峰表現訓練和創傷後壓力症候群（PTSD）。

對過動症和心理健康治療的需求

對注意力不足過動症 (ADHD) 和心理健康治療日益成長的需求是推動神經回饋平台廣泛應用的主要動力。這是因為臨床醫生和患者都在尋求非藥物、無副作用的干涉措施來治療注意力不足過動症、焦慮症和憂鬱症，尤其是對於那些對藥物治療無效的患者群體。美國食品藥物管理局 (FDA)核准基於神經反饋的 ADHD 療法，確立了其監管合法性，擴大了保險覆蓋範圍，並提高了醫生轉診的可信度。越來越多的家長傾向於為兒童患者選擇非興奮劑類 ADHD 干預措施，這推動了消費者對經認證的臨床神經反饋計畫的需求，從而導致臨床心理學和兒童神經病學領域對神經反饋平台的持續成長。

臨床證據與保險報銷之間的差距。

臨床證據品質的差異以及保險報銷範圍的限制是神經回饋技術推廣應用的主要障礙。這是因為，由於缺乏衛生技術評估機構核准保險覆蓋所需的循證隨機對照試驗，神經反饋平台提供者難以獲得保險公司的報銷。臨床研究中神經回饋方案、電極放置標準和結果測量方法的異質性限制了透過薈萃分析整合證據以加強報銷的努力。在無保險市場中，高昂的自費治療費用造成了就醫障礙，限制了神經回饋技術的普及，使其僅限於高所得患者群體，並限制了潛在市場（TAM）在專業私人醫療保健環境之外的發展。

提供遠端和居家神經回饋

將價格親民的消費級腦電圖（EEG）頭戴設備與遠端醫療平台結合，可以實現居家監督訓練項目，從而消除地域限制，減輕服務不足或行動不便地區患者的就診負擔。因此，遠端和居家神經回饋療法的提供為大幅擴大服務覆蓋範圍提供了重要機會。德國、日本和美國正在不斷完善的數位療法法規結構，為透過認證平台訂閱提供的處方箋位神經回饋計畫創建了報銷途徑。與診所治療方案相比，居家訓練的單次治療成本大幅降低，其經濟效益顯著，正在擴大能夠從大規模、持續性神經反饋干預中獲益的患者群體。

相互競爭的數位治療方法

來自FDA已通過核准的數位療法應用程式的競爭日益激烈，這些應用程式透過認知行為療法、生物回饋療法和遊戲化等行為干涉手段，治療注意力不足過動症（ADHD）、焦慮症和憂鬱症，對神經反饋療法構成商業性威脅。這是因為擁有更強臨床證據的競爭平台可能會在保險報銷和醫生推薦方面獲得優先權，從而擠佔神經反饋療法的市場佔有率。數位療法與製藥公司的合作，透過提供藥物和數位支援項目相結合的套餐，加劇了保險報銷管道的競爭。如果沒有類似的商業基礎設施，獨立的神經回饋平台營運商將難以與之競爭。此外，面向消費者的冥想和正念應用程式也在爭奪消費者的時間和預算，這與面向消費者的神經反饋訂閱服務類似。

新冠疫情的影響：

新冠疫情引發了一場嚴重的心理健康危機，大大提高了公眾對注意力不足過動症（ADHD）、焦慮症和壓力相關障礙（神經反饋平台的目標疾病）的認知度和治療需求，並催生了遠超疫情初期階段的持續需求成長。疫情期間遠端醫療監管的放寬使得遠距神經回饋療程得以開展，並加深了臨床醫生和患者對數位心理健康干預方法的理解。疫情後對心理健康技術平台的投資，持續為神經反饋平台的開發和商業化項目提供資金支持，這些項目在疫情期間就已吸引了數位健康投資者的關注。

在預測期內，服務業預計將佔據最大佔有率。

在預測期內，服務板塊預計將佔據最大的市場佔有率。這是因為基於訂閱的臨床療程交付模式能夠產生持續性收入，其價值遠超成熟神經回饋診所一次性購買硬體的成本。透過託管服務合約提供全面療程管理、臨床醫生培訓和認證、方案庫訪問以及患者進展分析的平台提供商，相比僅提供硬體的收費，能夠獲得更高的客戶維繫率和帳戶終身收入。遠距治療服務的擴展增加了每個平台計費的神經回饋療程數量，從而加速了業務收益的成長，使其高於硬體和軟體板塊。

在預測期內，腦電圖神經回饋領域預計將呈現最高的複合年成長率。

在預測期內，腦電圖（EEG）神經反饋領域預計將呈現最高的成長率，這主要得益於消費級EEG頭戴設備成本的快速下降，從而擴大了臨床和家庭市場；臨床方案標準化方面的進展提高了治療效果的一致性；以及在主要市場，醫保報銷範圍擴大，將EEG神經反饋作為多動症和焦慮症的適應症。無線乾電極EEG系統無需塗抹凝膠，顯著提高了患者的接受度和治療依從性，從而增強了醫保報銷談判中臨床療效的證據。此外，智慧型手機連接的EEG系統支援患者在診療間隙進行居家持續訓練，這為傳統的按診療次數收費模式之外開闢了新的訂閱收入來源。

市佔率最大的地區：

在整個預測期內，北美預計將保持最大的市場佔有率。這主要歸功於美國較高的注意力不足過動症（ADHD）診斷率和治療率，從而產生了巨大的臨床需求；ADHD治療中神經反饋療法的保險覆蓋範圍不斷擴大；以及北美擁有成熟的臨床神經反饋從業者群體，他們積極採用數位化平台工具。總部位於美國的神經回饋平台公司，例如Br​​ainMaster Technologies和BrainTrain Inc.，都擁有穩定的臨床基本客群。美國強大的心理健康技術投資生態系統和完善的數位醫療報銷體系，正在為北美的平台創新和商業性領先地位提供支援。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率。這主要歸功於以往服務不足人口對注意力不足過動症（ADHD）和心理健康治療方法的認知度迅速提高，醫療基礎設施的擴展使得神經回饋臨床服務得以開展，以及中國、日本、澳洲和韓國政府在心理健康領域的投資計畫。隨著亞太地區精神科評估基礎設施的完善，ADHD的診斷率不斷上升，從而推動了對臨床平台採購的需求。中國和韓國本土神經回饋平台開發商生態系統的興起，正在提升該地區市場的接受度。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要企業進行SWOT分析（最多3家公司）
  • 區域分類
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對主要企業進行基準分析。

目錄

第1章：執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球神經回饋平台市場：按組件分類

  • 硬體
    • 電極類型
  • 軟體
  • 服務

第6章 全球神經回饋平台市場：按模式分類

  • 腦電圖神經回饋
  • 功能性磁振造影神經回饋
  • HEG神經回饋
  • SCP神經回饋

第7章 全球神經回饋平台市場：依平台類型分類

  • 獨立系統
  • 基於雲端的平台

第8章 全球神經回饋平台市場：依年齡層別分類

  • 兒童
  • 成人
  • 老年人

第9章 全球神經回饋平台市場：按應用分類

  • 過動症治療
  • 焦慮和憂鬱症的管理
  • 睡眠障礙
  • 認知功能改善
  • 疼痛管理
  • 其他用途

第10章 全球神經回饋平台市場：依最終用戶分類

  • 醫院和診所
  • 健康中心
  • 研究機構
  • 普通家庭用戶
  • 其他最終用戶

第11章 全球神經回饋平台市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第12章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第13章：公司簡介

  • BrainMaster Technologies
  • Thought Technology Ltd.
  • NeuroCare Group
  • Mitsar Co. Ltd.
  • EEGer
  • BrainTrain Inc.
  • Neurofield Inc.
  • Zengar Institute
  • Cygnet Software
  • Neurobit Systems
  • Emotiv Inc.
  • OpenBCI
  • Natus Medical
  • Compumedics Neuroscan
  • Advanced Brain Monitoring
  • ANT Neuro
  • NeuroSky
  • BrainCo
Product Code: SMRC34840

According to Stratistics MRC, the Global Neurofeedback Platforms Market is accounted for $1.3 billion in 2026 and is expected to reach $3.4 billion by 2034 growing at a CAGR of 12.7% during the forecast period. Neurofeedback platforms refer to integrated clinical and consumer systems that measure real-time brain electrical activity through EEG, functional magnetic resonance imaging, hemoencephalography, or slow cortical potential recording, and provide immediate auditory, visual, or haptic feedback signals that train users to self-regulate specific neural oscillation patterns associated with attention, relaxation, cognitive performance, and neurological symptom management. These platforms encompass electrode headsets, signal amplification hardware, real-time signal processing software, gamified training interfaces, session management portals, and progress tracking analytics serving ADHD treatment, anxiety management, peak performance training, and post-traumatic stress disorder therapies.

Market Dynamics:

Driver:

ADHD and Mental Health Treatment Demand

Escalating ADHD and mental health treatment demand is the primary driver expanding neurofeedback platform adoption as clinicians and patients seek non-pharmacological, side-effect-free interventions for attention deficit disorders, anxiety, and depression that medication-resistant patient populations particularly require. FDA clearance of neurofeedback-based ADHD treatments has established regulatory legitimacy that is expanding insurance reimbursement coverage and physician referral confidence. Growing parental preference for non-stimulant ADHD interventions for pediatric patients is generating strong consumer demand for certified clinical neurofeedback programs that creates sustained platform procurement growth across clinical psychology and pediatric neurology practice settings.

Restraint:

Clinical Evidence and Reimbursement Gaps

Inconsistent clinical evidence quality and limited insurance reimbursement coverage represent significant adoption barriers as neurofeedback platform operators struggle to secure payer coverage without the randomized controlled trial evidence bases that health technology assessment bodies require for positive coverage determinations. Heterogeneity of neurofeedback protocols, electrode placement standards, and outcome measurement approaches across clinical studies limits meta-analytic evidence synthesis that would strengthen reimbursement advocacy. High out-of-pocket session costs in markets without coverage create access barriers that confine neurofeedback adoption to higher-income patient segments and constrain total addressable market development beyond specialty private pay clinical settings.

Opportunity:

Remote and Home-Based Neurofeedback Delivery

Remote and home-based neurofeedback delivery represents a transformational access expansion opportunity as affordable consumer-grade EEG headsets and telehealth platform integration enable supervised at-home training programs that eliminate geographic access barriers and session attendance burden for patients in underserved rural or mobility-constrained populations. Digital therapeutics regulatory frameworks emerging in Germany, Japan, and the United States are creating reimbursement pathways for prescription digital neurofeedback programs delivered through certified platform subscriptions. Home training economics with dramatically reduced per-session cost compared to clinic-based protocols are expanding the viable patient population for sustained neurofeedback intervention at scale.

Threat:

Competing Digital Therapeutics Modalities

Competition from FDA-cleared digital therapeutic applications addressing ADHD, anxiety, and depression through cognitive behavioral therapy, biofeedback, and gamified behavioral intervention modalities represents a growing commercial threat as competing platforms with stronger clinical evidence bases may preferentially capture reimbursement coverage and physician recommendation at the expense of neurofeedback alternatives. Pharmaceutical company digital therapy partnerships creating bundled medication and digital support programs are generating competing reimbursement-supported access pathways that independent neurofeedback platform operators cannot match without equivalent commercial infrastructure. Direct-to-consumer meditation and mindfulness apps capturing discretionary mental wellness spending are competing for the same consumer time and budget allocation as consumer neurofeedback subscriptions.

Covid-19 Impact:

COVID-19 generated a significant mental health crisis that substantially expanded public awareness and treatment-seeking behavior for ADHD, anxiety, and stress-related conditions that neurofeedback platforms address, creating demand growth that persisted well beyond initial pandemic phases. Telehealth regulatory liberalizations during the pandemic period enabled remote neurofeedback session delivery that expanded clinician and patient familiarity with digital mental health intervention modalities. Post-pandemic investment in mental health technology platforms has sustained capital availability for neurofeedback platform development and commercialization programs that benefited from pandemic-era digital health investor attention.

The services segment is expected to be the largest during the forecast period

The services segment is expected to account for the largest market share during the forecast period, due to the subscription-based clinical session delivery model generating recurring revenue that substantially exceeds one-time hardware procurement values in established neurofeedback practice accounts. Platform operators providing comprehensive session management, clinician training certification, protocol library access, and patient progress analytics through managed service arrangements are achieving superior customer retention and lifetime account revenue versus hardware-only vendor relationships. Teletherapy delivery expansion is increasing the volume of billable neurofeedback sessions per platform installation, amplifying services revenue growth relative to hardware and software segments.

The EEG neurofeedback segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the EEG neurofeedback segment is predicted to witness the highest growth rate, driven by rapidly declining consumer EEG headset costs that are expanding the addressable clinical and home-use market, growing clinical protocol standardization improving treatment outcome consistency, and expanding insurance reimbursement coverage in major markets recognizing EEG neurofeedback for ADHD and anxiety indications. Wireless dry-electrode EEG systems eliminating gel preparation burden are significantly improving patient acceptance and session compliance rates that improve clinical outcome evidence for reimbursement negotiations. Smartphone-connected EEG systems enabling continuous home training between clinic sessions are generating new subscription revenue streams beyond traditional office-based session billing models.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to the high ADHD diagnosis and treatment rate in the United States generating large clinical demand, growing insurance plan coverage for neurofeedback ADHD treatment, and established clinical neurofeedback practitioner community adopting digital platform tools. U.S.-based neurofeedback platform companies including BrainMaster Technologies and BrainTrain Inc. maintain established clinical customer bases. Strong mental health technology investment ecosystem and digital health reimbursement framework development in the United States sustains North American platform innovation and commercial leadership.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rapidly growing awareness of ADHD and mental health treatment options across previously underserved populations, expanding healthcare infrastructure enabling neurofeedback clinical service delivery, and government mental health investment programs in China, Japan, Australia, and South Korea. Rising ADHD diagnosis rates as psychiatric assessment infrastructure develops across Asia Pacific markets are generating growing clinical platform procurement demand. Domestic neurofeedback platform developer ecosystem emergence in China and South Korea is building regional market capacity.

Key players in the market

Some of the key players in Neurofeedback Platforms Market include BrainMaster Technologies, Thought Technology Ltd., NeuroCare Group, Mitsar Co. Ltd., EEGer, BrainTrain Inc., Neurofield Inc., Zengar Institute, Cygnet Software, Neurobit Systems, Emotiv Inc., OpenBCI, Natus Medical, Compumedics Neuroscan, Advanced Brain Monitoring, ANT Neuro, NeuroSky, and BrainCo.

Key Developments:

In March 2026, OpenBCI introduced the Galea Gen 2 multimodal biosensing headset combining EEG, EMG, and eye tracking for combined neurofeedback and biofeedback research and clinical training protocols.

In February 2026, Thought Technology Ltd. released the ProComp Infiniti 8 multichannel biofeedback and neurofeedback system with enhanced wireless EEG acquisition and integrated teletherapy session delivery capabilities.

In December 2025, NeuroCare Group launched its cloud-based neurofeedback protocol management platform integrating AI-driven session personalization and remote therapist supervision for multi-site clinical network deployment.

Components Covered:

  • Hardware
  • Software
  • Services

Modalities Covered:

  • EEG Neurofeedback
  • fMRI Neurofeedback
  • HEG Neurofeedback
  • SCP Neurofeedback

Platform Types Covered:

  • Standalone Systems
  • Cloud-Based Platforms

Age Groups Covered:

  • Pediatric
  • Adults
  • Geriatric

Applications Covered:

  • ADHD Treatment
  • Anxiety & Depression Management
  • Sleep Disorders
  • Cognitive Enhancement
  • Pain Management
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Wellness Centers
  • Research Institutions
  • Home Users
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Neurofeedback Platforms Market, By Component

  • 5.1 Hardware
    • 5.1.1 Electrode Type
  • 5.2 Software
  • 5.3 Services

6 Global Neurofeedback Platforms Market, By Modality

  • 6.1 EEG Neurofeedback
  • 6.2 fMRI Neurofeedback
  • 6.3 HEG Neurofeedback
  • 6.4 SCP Neurofeedback

7 Global Neurofeedback Platforms Market, By Platform Type

  • 7.1 Standalone Systems
  • 7.2 Cloud-Based Platforms

8 Global Neurofeedback Platforms Market, By Age Group

  • 8.1 Pediatric
  • 8.2 Adults
  • 8.3 Geriatric

9 Global Neurofeedback Platforms Market, By Application

  • 9.1 ADHD Treatment
  • 9.2 Anxiety & Depression Management
  • 9.3 Sleep Disorders
  • 9.4 Cognitive Enhancement
  • 9.5 Pain Management
  • 9.6 Other Applications

10 Global Neurofeedback Platforms Market, By End User

  • 10.1 Hospitals & Clinics
  • 10.2 Wellness Centers
  • 10.3 Research Institutions
  • 10.4 Home Users
  • 10.5 Other End Users

11 Global Neurofeedback Platforms Market, By Geography

  • 11.1 North America
    • 11.1.1 United States
    • 11.1.2 Canada
    • 11.1.3 Mexico
  • 11.2 Europe
    • 11.2.1 United Kingdom
    • 11.2.2 Germany
    • 11.2.3 France
    • 11.2.4 Italy
    • 11.2.5 Spain
    • 11.2.6 Netherlands
    • 11.2.7 Belgium
    • 11.2.8 Sweden
    • 11.2.9 Switzerland
    • 11.2.10 Poland
    • 11.2.11 Rest of Europe
  • 11.3 Asia Pacific
    • 11.3.1 China
    • 11.3.2 Japan
    • 11.3.3 India
    • 11.3.4 South Korea
    • 11.3.5 Australia
    • 11.3.6 Indonesia
    • 11.3.7 Thailand
    • 11.3.8 Malaysia
    • 11.3.9 Singapore
    • 11.3.10 Vietnam
    • 11.3.11 Rest of Asia Pacific
  • 11.4 South America
    • 11.4.1 Brazil
    • 11.4.2 Argentina
    • 11.4.3 Colombia
    • 11.4.4 Chile
    • 11.4.5 Peru
    • 11.4.6 Rest of South America
  • 11.5 Rest of the World (RoW)
    • 11.5.1 Middle East
      • 11.5.1.1 Saudi Arabia
      • 11.5.1.2 United Arab Emirates
      • 11.5.1.3 Qatar
      • 11.5.1.4 Israel
      • 11.5.1.5 Rest of Middle East
    • 11.5.2 Africa
      • 11.5.2.1 South Africa
      • 11.5.2.2 Egypt
      • 11.5.2.3 Morocco
      • 11.5.2.4 Rest of Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 BrainMaster Technologies
  • 13.2 Thought Technology Ltd.
  • 13.3 NeuroCare Group
  • 13.4 Mitsar Co. Ltd.
  • 13.5 EEGer
  • 13.6 BrainTrain Inc.
  • 13.7 Neurofield Inc.
  • 13.8 Zengar Institute
  • 13.9 Cygnet Software
  • 13.10 Neurobit Systems
  • 13.11 Emotiv Inc.
  • 13.12 OpenBCI
  • 13.13 Natus Medical
  • 13.14 Compumedics Neuroscan
  • 13.15 Advanced Brain Monitoring
  • 13.16 ANT Neuro
  • 13.17 NeuroSky
  • 13.18 BrainCo

List of Tables

  • Table 1 Global Neurofeedback Platforms Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Neurofeedback Platforms Market Outlook, By Component (2023-2034) ($MN)
  • Table 3 Global Neurofeedback Platforms Market Outlook, By Hardware (2023-2034) ($MN)
  • Table 4 Global Neurofeedback Platforms Market Outlook, By Electrode Type (2023-2034) ($MN)
  • Table 5 Global Neurofeedback Platforms Market Outlook, By Software (2023-2034) ($MN)
  • Table 6 Global Neurofeedback Platforms Market Outlook, By Services (2023-2034) ($MN)
  • Table 7 Global Neurofeedback Platforms Market Outlook, By Modality (2023-2034) ($MN)
  • Table 8 Global Neurofeedback Platforms Market Outlook, By EEG Neurofeedback (2023-2034) ($MN)
  • Table 9 Global Neurofeedback Platforms Market Outlook, By fMRI Neurofeedback (2023-2034) ($MN)
  • Table 10 Global Neurofeedback Platforms Market Outlook, By HEG Neurofeedback (2023-2034) ($MN)
  • Table 11 Global Neurofeedback Platforms Market Outlook, By SCP Neurofeedback (2023-2034) ($MN)
  • Table 12 Global Neurofeedback Platforms Market Outlook, By Platform Type (2023-2034) ($MN)
  • Table 13 Global Neurofeedback Platforms Market Outlook, By Standalone Systems (2023-2034) ($MN)
  • Table 14 Global Neurofeedback Platforms Market Outlook, By Cloud-Based Platforms (2023-2034) ($MN)
  • Table 15 Global Neurofeedback Platforms Market Outlook, By Age Group (2023-2034) ($MN)
  • Table 16 Global Neurofeedback Platforms Market Outlook, By Pediatric (2023-2034) ($MN)
  • Table 17 Global Neurofeedback Platforms Market Outlook, By Adults (2023-2034) ($MN)
  • Table 18 Global Neurofeedback Platforms Market Outlook, By Geriatric (2023-2034) ($MN)
  • Table 19 Global Neurofeedback Platforms Market Outlook, By Application (2023-2034) ($MN)
  • Table 20 Global Neurofeedback Platforms Market Outlook, By ADHD Treatment (2023-2034) ($MN)
  • Table 21 Global Neurofeedback Platforms Market Outlook, By Anxiety & Depression Management (2023-2034) ($MN)
  • Table 22 Global Neurofeedback Platforms Market Outlook, By Sleep Disorders (2023-2034) ($MN)
  • Table 23 Global Neurofeedback Platforms Market Outlook, By Cognitive Enhancement (2023-2034) ($MN)
  • Table 24 Global Neurofeedback Platforms Market Outlook, By Pain Management (2023-2034) ($MN)
  • Table 25 Global Neurofeedback Platforms Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 26 Global Neurofeedback Platforms Market Outlook, By End User (2023-2034) ($MN)
  • Table 27 Global Neurofeedback Platforms Market Outlook, By Hospitals & Clinics (2023-2034) ($MN)
  • Table 28 Global Neurofeedback Platforms Market Outlook, By Wellness Centers (2023-2034) ($MN)
  • Table 29 Global Neurofeedback Platforms Market Outlook, By Research Institutions (2023-2034) ($MN)
  • Table 30 Global Neurofeedback Platforms Market Outlook, By Home Users (2023-2034) ($MN)
  • Table 31 Global Neurofeedback Platforms Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.